Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases

Immunology

Volumn 133, Issue 2, 2011, Pages 206-220

  Puskas, John ^a   Skrombolas, Denise ^a   Sedlacek, Abigail ^a   Lord, Edith ^a   Sullivan, Mark ^a   Frelinger, John ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Cytokines; Fusion proteins; Interleukin 2; Proteases; Single chain antibodies; T cells; Tumour microenvironment

Indexed keywords

CYTOKINE ANTIBODY; GELATINASE A; GELATINASE B; HYBRID PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 ANTIBODY; INTERLEUKIN 2 RECEPTOR ALPHA; MATRIX METALLOPROTEINASE; PROSTATE SPECIFIC ANTIGEN; PROTEINASE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COLON TUMOR; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DISSOCIATION; DRUG DETERMINATION; ENZYME ACTIVE SITE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOBLOTTING; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS; PROSTATE-SPECIFIC ANTIGEN; RECOMBINANT PROTEINS;

EID: 79955023417     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2011.03428.x     Document Type: Article

References (74)

1. Finn OJ. Cancer immunology. N Engl J Med 2008; 358:2704-15.
2. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24:175-208.
3. Parmiani G, De Filippo A, Novellino L, Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol 2007; 178:1975-9.
4. Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004; 113:1515-25.
5. Slingluff CL Jr, Chianese-Bullock KA, Bullock TN et al. Immunity to melanoma antigens: from self-tolerance to immunotherapy. Adv Immunol 2006; 90:243-95.
6. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995; 13:399-415.
7. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411:380-4.
8. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271:907-13.
9. Den Otter W, Jacobs JJ, Battermann JJ et al. Local therapy of cancer with free IL-2. Cancer Immunol Immunother 2008; 57:931-50.
10. Hanes J, Sills A, Zhao Z et al. Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm Res 2001; 18:899-906.
11. Egilmez NK, Jong YS, Sabel MS, Jacob JS, Mathiowitz E, Bankert RB. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res 2000; 60:3832-7.
12. + CTL and NK cells. Surgery 2007; 142:749-60.
13. Sangro B, Mazzolini G, Ruiz J et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004; 22:1389-97.
14. Triozzi PL, Allen KO, Carlisle RR, Craig M, LoBuglio AF, Conry RM. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin Cancer Res 2005; 11:4168-75.
15. Addison CL, Braciak T, Ralston R, Muller WJ, Gauldie J, Graham FL. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci U S A 1995; 92:8522-6.
16. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172:1217-24.
17. McAdam AJ, Pulaski BA, Harkins SS, Hutter EK, Lord EM, Frelinger JG. Synergistic effects of co-expression of the TH1 cytokines IL-2 and IFN-gamma on generation of murine tumor-reactive cytotoxic cells. Int J Cancer 1995; 61:628-34.
18. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003; 21:383-91.
19. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89:1260-70.
20. Malek TR. The biology of interleukin-2. Annu Rev Immunol 2008; 26:453-79.
21. Bachmann MF, Oxenius A. Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep 2007; 8:1142-8.
22. Haidaris CG, Malone J, Sherrill LA, Bliss JM, Gaspari AA, Insel RA, Sullivan MA. Recombinant human antibody single chain variable fragments reactive with Candida albicans surface antigens. J Immunol Methods 2001; 257:185-202.
23. Malone J, Sullivan MA. Analysis of antibody selection by phage display utilizing anti-phenobarbital antibodies. J Mol Recognit 1996; 9:738-45.
24. Mehlin C, Boni E, Buckner FS et al. Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. Mol Biochem Parasitol 2006; 148:144-60.
25. Rose RC, Bonnez W, Strike DG, Reichman RC. Expression of the full-length products of the human papillomavirus type 6b (HPV-6b) and HPV-11L2 open reading frames by recombinant baculovirus, and antigenic comparisons with HPV-11 whole virus particles. J Gen Virol 1990; 71(Pt 11):2725-9.
26. Rose RC, Bonnez W, Da Rin C, McCance DJ, Reichman RC. Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J Gen Virol 1994; 75(Pt 9):2445-9.
27. Turner MJ, Abdul-Alim CS, Willis RA, Fisher TL, Lord EM, Frelinger JG. T-cell antigen discovery (T-CAD) assay: a novel technique for identifying T cell epitopes. J Immunol Methods 2001; 256:107-19.
28. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
29. Young FM, Phungtamdet W, Sanderson BJ. Modification of MTT assay conditions to examine the cytotoxic effects of amitraz on the human lymphoblastoid cell line, WIL2NS. Toxicol In Vitro 2005; 19:1051-9.
30. Wei C, Willis RA, Tilton BR, Looney RJ, Lord EM, Barth RK, Frelinger JG. Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy. Proc Natl Acad Sci U S A 1997; 94:6369-74.
31. Fisher TL, Nocera M, Willis RA et al. Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors. Prostate 2002; 51:153-65.
32. Sorensen EW, Gerber SA, Sedlacek AL, Rybalko VY, Chan WM, Lord EM. Omental immune aggregates and tumor metastasis within the peritoneal cavity. Immunol Res 2009; 45:185-194.
33. Lord EM, Burkhardt G. Assessment of in situ host immunity to syngeneic tumors utilizing the multicellular spheroid model. Cell Immunol 1984; 85:340-50.
34. Denmeade SR, Lou W, Lovgren J, Malm J, Lilja H, Isaacs JT. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 1997; 57:4924-30.
35. Minami Y, Kono T, Miyazaki T, Taniguchi T. The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol 1993; 11:245-68.
36. 3 linker sequence results in enhanced protein expression. Mol Immunol 2004; 40:717-22.
37. Chen EI, Kridel SJ, Howard EW, Li W, Godzik A, Smith JW. A unique substrate recognition profile for matrix metalloproteinase-2. J Biol Chem 2002; 277:4485-91.
38. Gerber SA, Rybalko VY, Bigelow CE, Lugade AA, Foster TH, Frelinger JG, Lord EM. Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol 2006; 169:1739-52.
39. Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ. Matrix metalloproteinases in human melanoma. J Invest Dermatol 2000; 115:337-44.
40. Bergers G, Brekken R, McMahon G et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2:737-44.
41. Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kahari VM, Pyrhonen S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 2005; 11:5158-66.
42. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:161-74.
43. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 2001; 7:743-8.
44. Lilja H. Biology of prostate-specific antigen. Urology 2003; 5(Suppl. 1):27-33.
45. Schroder FH, Roach M III, Scardino P. Clinical decisions. Management of prostate cancer. N Engl J Med 2008; 359:2605-9.
46. Heaney ML, Golde DW. Soluble cytokine receptors. Blood 1996; 87:847-57.
47. Smith KA. The structure of IL2 bound to the three chains of the IL2 receptor and how signaling occurs. Med Immunol 2006; 5:3.
48. Shimotsuma M, Shields JW, Simpson-Morgan MW, Sakuyama A, Shirasu M, Hagiwara A, Takahashi T. Morpho-physiological function and role of omental milky spots as omentum-associated lymphoid tissue (OALT) in the peritoneal cavity. Lymphology 1993; 26:90-101.
49. Oosterling SJ, van der Bij GJ, Bogels M, van der Sijp JR, Beelen RH, Meijer S, van Egmond M. Insufficient ability of omental milky spots to prevent peritoneal tumor outgrowth supports omentectomy in minimal residual disease. Cancer Immunol Immunother 2006; 55:1043-51.
50. Krist LF, Kerremans M, Broekhuis-Fluitsma DM, Eestermans IL, Meyer S, Beelen RH. Milky spots in the greater omentum are predominant sites of local tumour cell proliferation and accumulation in the peritoneal cavity. Cancer Immunol Immunother 1998; 47:205-12.
51. Vlad AM, Budiu RA, Lenzner DE et al. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother 2009; 59:293-301.
52. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol 2008; 20:241-6.
53. Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J Clin Invest 1996; 98:2801-4.
54. Dela Cruz JS, Huang TH, Penichet ML, Morrison SL. Antibody-cytokine fusion proteins: innovative weapons in the war against cancer. Clin Exp Med 2004; 4:57-64.
55. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006; 5:147-59.
56. Adams G, Vessillier S, Dreja H, Chernajovsky Y. Targeting cytokines to inflammation sites. Nat Biotechnol 2003; 21:1314-20.
57. Allione A, Consalvo M, Nanni P et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 1994; 54:6022-6.
58. Porgador A, Gansbacher B, Bannerji R, Tzehoval E, Gilboa E, Feldman M, Eisenbach L. Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Int J Cancer 1993; 53:471-7.
59. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993; 90:3539-43.
60. Roth C, Mir LM, Cressent M, Quintin-Colonna F, Ley V, Fradelizi D, Kourilsky P. Inhibition of tumor growth by histoincompatible cells expressing interleukin-2. Int Immunol 1992; 4:1429-36.
61. McAdam AJ, Pulaski BA, Storozynsky E, Yeh KY, Sickel JZ, Frelinger JG, Lord EM. Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor. Cell Immunol 1995; 165:183-92.
62. Woods ML, McAdam AJ, Frelinger JG, Lord EM. Isolation and expansion of tumor-infiltrating lymphocytes. BioTechniques 1993; 15:970-2.
63. Lee PP, Yee C, Savage PA et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5:677-85.
64. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 1999; 162:2227-34.
65. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314:126-9.
66. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308.
67. McKarney I. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer. Issues Emerg Health Technol 2007; 101:1-4.
68. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22.
69. Longo DL. New therapies for castration-resistant prostate cancer. N Engl J Med ????; 363:479-81.
70. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3:133-46.
71. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74.
72. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182:4499-506.
73. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25:267-96.
74. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5:263-74.